×

Intellectual Property Patents

  • Patent Trial and Appeal Board, the Saint Regis Mohawk Tribe asked that Mylan's case seeking to invalidate Allergan's patents on dry-eye medicine Restasis be thrown out on the grounds that the board has no jurisdiction over the tribe. In its court filing on Friday, the tribe said it is sovereign government that cannot face litigation in an administrative court...

  • Sept 22- A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents. Patent Trial and Appeal Board, the Saint Regis Mohawk Tribe asked that Mylan's case seeking to invalidate Allergan's patents on dry-eye medicine Restasis be thrown out on the grounds...

  • TRIBE SAYS ITS SOVEREIGN STATUS IMMUNIZES RESTASIS PATENTS FROM U.S.

  • ST REGIS MOHAWK TRIBE MOVES TO DISMISS MYLAN CHALLENGE TO ALLERGAN PATENTS- FILING.

  • HELSINKI, Sept 18- Nokia will start to book additional revenue from the current quarter after a ruling by an arbitration court on payments from South Korea's LG Electronics for using its smartphone patents. We continue to see potential for additional licensing opportunities, "said Nokia Chief Legal Officer Maria Varsellona in a statement.

  • The Ohio Democrat said he will look at how Congress can "close loopholes that drug companies exploit to avoid competition. Allergan said it has reached out to Brown's office "to provide the facts and context around this agreement with the Saint Regis Mohawk Tribe." Allergan said on Sept. 8 it will transfer patents relating to its dry-eye medicine Restasis to the...

  • The Ohio Democrat said he will look at how Congress can "close loopholes that drug companies exploit to avoid competition. Allergan said it has reached out to Brown's office "to provide the facts and context around this agreement with the Saint Regis Mohawk Tribe." Allergan said on Sept. 8 it will transfer patents relating to its dry-eye medicine Restasis to the...

  • Reddy's, Allergan Plc's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV. The lawsuits allege that these companies have infringed a patent that relates to an oral film containing buprenorphine and naloxone, the key constituents of Suboxone, the London- listed drugmaker said in a...

  • Sept 13- As generic drug manufacturers are. Last week, Allergan announced it would transfer the patent rights to its Restasis dry-eye treatment to the Saint Regis Mohawk Tribe, which will license them back to the company in exchange for ongoing payments. But Richard Torczon, a lawyer for generic drug company Mylan.

  • DOVER, Del.— An Arizona-based pharmaceutical company targeted in lawsuits and criminal investigations over its marketing of a highly addictive painkiller has filed a related patent-infringement lawsuit against a rival drug maker. Insys Therapeutics filed the complaint against Teva Pharmaceuticals on Wednesday in federal court in Delaware.

  • Patent and Trademark Office records, SRC Labs LLC on Aug. 2 transferred around 40 patents to the St. Regis Mohawk Tribe. The deals announced so far "are just the tip of the iceberg," said David Pridham, chief executive of Dominion Harbor Group, a Dallas- based firm that advises patent owners on monetization efforts. Headed by Dallas lawyer, entrepreneur and investment...

  • NEW YORK, Sept 12- Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis. In Federal District Court in Marshall, Texas, on Monday, Mylan said Allergan is "attempting to misuse Native American sovereignty to shield...

  • Sept 12- A groundbreaking deal between Allergan Plc and a Native American tribe to shield the company's patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts said, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry...

  • Sept 11- A groundbreaking deal between Allergan Plc and a Native American tribe to shield the company's patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts said, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry...

  • Sept 8- Allergan Plc will transfer to the Saint Regis Mohawk Tribe the rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. The tribe, which has sovereign immunity from such challenges, will receive a one-time payment of $13.75 million and annual royalties of around $15...

  • Brent Saunders, president and CEO of Allergan.

    Allergan transferred patents for its eye drug Restasis to the Saint Regis Mohawk Tribe, which then granted it back an exclusive license.

  • Sept 8- Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. The tribe, which has sovereign immunity from such challenges, will receive a one-time payment of $13.75 million and annual royalties of around $15 million...

  • Sept 5- A federal judge in Delaware on Tuesday invalidated patents held by Mallinckrodt Pharmaceuticals on its Inomax respiratory treatment system. Mallinckrodt noted it had regulatory exclusivity for the treatment until October 2018. Mallinckrodt shares have been targeted by short sellers, with 18.6 percent of the shares outstanding held as short...

  • Sept 1- Shares in London- listed Indivior plunged 40 percent after the drugmaker said a U.S. court ruling could clear the way for a generic rival to its treatment for opioid addiction that generates 80 percent of its revenues. Indivior said the Delaware District Court ruling meant it would not be able to rely on patents to prevent Indian firm Dr.Reddy' s from making...

  • Sept 1- Shares in Indivior plunged 40 percent on Friday after it said a U.S. court ruling could lead to a generic rival to its treatment for opioid addiction that generates 80 percent of the London- listed drug maker's revenues. Indivior has said it would not be able to rely on patents to prevent Indian firm Dr.Reddy' s from making and marketing a generic alternative...